Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the period ending June 28, 2024. The report discloses the execution of a Sales Agreement with Leerink Partners LLC to facilitate an "at-the-market" offering of the Company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate transaction rather than a financial results statement.
Material Changes
The primary material change is the establishment of an "at-the-market" equity offering program. The Company entered into a Sales Agreement with Leerink Partners LLC on June 28, 2024, authorizing the sale of ordinary shares through this mechanism.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the standard disclosure of the new sales agreement. The agreement is incorporated by reference into the Company's existing registration statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the terms of the Sales Agreement with Leerink Partners LLC (Exhibit 99.1) regarding commission rates and share limits.
- Monitor subsequent filings for actual share sales executed under this "at-the-market" program.
- Review the Company's most recent Form 20-F for current cash position and liquidity status, as this 6-K does not provide updated financial figures.